Horizon Therapeutics PLC (HZNP) News

Horizon Therapeutics PLC (HZNP): $80.84

1.08 (+1.35%)

POWR Rating

Component Grades













Filter HZNP News Items

HZNP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HZNP News Highlights

  • HZNP's 30 day story count now stands at 42.
  • Over the past 21 days, the trend for HZNP's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
  • The most mentioned tickers in articles about HZNP are RARE, BODY and NYT.

Latest HZNP News From Around the Web

Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

DUBLIN, February 23, 2022--Horizon Therapeutics announces the initiation of a Phase 3 trial (OPTIC-J) in Japan evaluating teprotumumab for the treatment of active TED.

Yahoo | February 23, 2022

Horizon Therapeutics Brings in Big Money

Horizon Therapeutics Public Limited Company (HZNP) stock has been hot recently, gaining 8.0% over the past month.

FX Empire | February 22, 2022

Horizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference

DUBLIN, February 21, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will present at the following conference in March:

Yahoo | February 21, 2022

Horizon Therapeutics'' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation

Horizon Therapeutics plc (NASDAQ: HZNP ) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis Optica Spectrum Disorder (NMOSD) . The data will be presented at the 48th Annual Meeting of the North American Neuro-Ophthalmology Society. NMOSD is a neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord, brain, and … Full story available on Benzinga.com

Benzinga | February 16, 2022

Horizon''s Uplizna reduces severity of attacks in neuro disease

Horizon Therapeutics (HZNP) said a new analysis showed that Uplizna reduced the severity of attacks and levels of key disease-related biomarkers in people with Neuromyelitis…

Seeking Alpha | February 16, 2022

Horizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel

DUBLIN, February 16, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today named Sean Clayton as executive vice president and general counsel effective Feb. 28. Sean will report directly to Tim Walbert, chairman, president and chief executive officer and will join the Company’s executive committee.

Yahoo | February 16, 2022

New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)

DUBLIN, February 16, 2022--Horizon Therapeutics plc announced results from an analysis showing treatment with UPLIZNA effectively reduced the severity of attacks in NMOSD.

Yahoo | February 16, 2022

Local Non-Profit Partners with Rock Legend to Fight Rare Disease

CHICAGO , Feb. 15, 2022 /PRNewswire-PRWeb/ -- Harmony 4 Hope, a non-profit organization merging music and storytelling to provide funding for the research of rare diseases, is teaming up with Grammy Award winner and NYT Best Selling Author Peter Frampton to raise awareness for rare disease. Together with the Genomic Sciences and Precision Medicine Center at the Medical College of Wisconsin , Children''s Hospital of Wisconsin , Johns Hopkins Medicine , and sponsor Horizon Therapeutics , Harmony 4 Hope is proud to welcome Peter Frampton as a guest at their upcoming Rare Storytellers event as he shares his story of living with Inclusion Body Myositis and his diagnostic journey. "We could not be more pleased to welcome Peter Frampton as a Rare Storyteller," said Kerry Hughes , Executive Dir...

Benzinga | February 15, 2022

Horizon analysis finds Tepezza hearing events similar to that seen in late-stage studies

An analysis conducted by Horizon Therapeutics (HZNP) on hearing-related adverse events associated with Tepezza found that they were at a rate similar to that seen in clinical studies.

Seeking Alpha | February 15, 2022

New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations

DUBLIN, February 15, 2022--Horizon Therapeutics announced results from a post-marketing safety analysis of TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease.

Yahoo | February 15, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5377 seconds.